Please assess the completion status of the following clinical trial:

Trial Title: Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants born before week 32 of gestation.~* Preterm infant who is less than 33 weeks postmenstrual age at the time of randomization.~* Preterm infant who is appropriate for gestational age (AGA) or small for gestational age (SGA) at birth.~* Preterm infant who is receiving food enterally (bottle or gavage tube) at a level of at least 100 ml/kg/day at randomization.~* Preterm infant whose enteral feeding consists of only infant formula or only pasteurized breast milk at the time of inclusion, and who are expected to remain on only infant formula for 4 weeks, or only pasteurized breast milk for at least 2 weeks following treatment initiation.~* Preterm infant who is expected not to receive any fresh breast milk for 4 weeks following treatment initiation.~* Informed consent is obtained.~Exclusion Criteria:~* Expected stay in the hospital is less than 4 weeks from the first dose of study drug.~* Criteria to ensure no disease or treatment affecting growth or development, e.g. brain disease, necrotizing enterocolitis.~* Enrolled in another concurrent clinical intervention study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 10 Weeks
- Healthy Volunteers: f

Study Arms:
- rhBSSL (Type: EXPERIMENTAL): rhBSSL (recombinant human bile-salt-stimulated lipase)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).